Trinity Biotech's TRIstat HbA1c test:
This article was originally published in Clinica
Irish diagnostics firm Trinity Biotech has gained US 510k approval of its TRIstat point-of-care HbA1c blood test. The TRIstat platform detects a patient's level of HbA1c, also known as glycated haemoglobin, a measure of their blood sugar control over the previous two to three months. The American Diabetes Association recommends that diabetic patients be tested for HbA1c at least four times a year. The test uses an affinity two-phase optical system, and can give results within minutes, the Dublin-based company claimed. Launch of the TRIstat product is slated for the first quarter of 2008. Trinity has not yet filed for CE-marking in Europe.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.